Nurix Therapeutics Inc at Barclays Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Peter Lawson - Barclays - Analyst : And with that, first question I've been asking series of companies and then mostly no impact kind of questions, but supply chain disruptions. Anything you're kind of thinking through and worried about just with tariffs? Or are you kind of prepped from COVID in a sense?

Question: Peter Lawson - Barclays - Analyst : Yes. Okay. Perfect. And then, FDA, I know it's kind of early days and fear of cuts there. Are you seeing any change in the speed of communication with the FDA or do you anticipate?

Question: Peter Lawson - Barclays - Analyst : Okay. Perfect. And then, I guess, a longer-term impact, very likely on innovation would, of course, be NIH budgetary cuts. Whether you share that

Question: Peter Lawson - Barclays - Analyst : So, on your pipeline, so the CLL study, so your BTK inhibitor, and I guess, the first question is like what we've seen so far? And what are we going to get from the next update, which I presume is probably kind of an ASH time frame, year-end-ish kind of time frame for the updates?

Question: Peter Lawson - Barclays - Analyst :

Question: Peter Lawson - Barclays - Analyst : What are the things -- what are the outcomes we should be thinking about as you think about the regulatory strategy and path?

Question: Peter Lawson - Barclays - Analyst : Would that confirmatory trial kind of move you into an earlier line? Or how do you think about that? Do you think about it as kind of additive potentially to the label or just confirming that label?

Question: Peter Lawson - Barclays - Analyst : Got you. And for that second-line setting, would that be monotherapy? Or is it better to combine? Or how do we think about it?

Question: Peter Lawson - Barclays - Analyst : Okay. And then, as we think about that first-line setting, what would be good combination agents? Are there things that are off the list or on the list that they can combine with or can't?

Question: Peter Lawson - Barclays - Analyst : And I guess, one triangulation point -- it's probably going to be difficult to ask, but like (inaudible) data set where they kind of didn't show it functioning in the broader group, but it works well in the ESR1 population. Are there any fears -- I guess, fundamentally, some investors, we were -- some KOLs were thinking, well, it's a different mechanism of action, so it's going to function differently from the other oral SERDs. Are there any worries that as you get into broader populations or earlier populations that it doesn't work as well? Just trying to make a tenuous link between two degraders.

Question: Peter Lawson - Barclays - Analyst : Perfect. And kind of as we think about that update, would you, I guess, break out efficacy with the lower dose like the 200 milligram versus the 600 milligram? Kind of what should we be thinking about how that data is broken out at here, whether it's EHA or mid-2025?

Question: Peter Lawson - Barclays - Analyst : Got you. Okay. And then, what's the appropriate bar? I guess, the other BTK inhibitors out there, again, [PFS is] like 14 months or so. Is that a sensible bar to get to?

Question: Peter Lawson - Barclays - Analyst : Exactly.

Question: Peter Lawson - Barclays - Analyst : Do you see a correlation of those response rates in PFS numbers and in CLL? Does that kind of add to confidence around moving the PFS number out? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 12, 2025 / 2:00PM, NRIX.OQ - Nurix Therapeutics Inc at Barclays Global Healthcare Conference

Question: Peter Lawson - Barclays - Analyst : Got you. And then, how do you think your -- I guess, the comparison between you and BeiGene or BeOne Medicines, how those BTK inhibitors are kind of shaking out? Is it more similar than dissimilar or --

Question: Peter Lawson - Barclays - Analyst : Okay. At what point do you think that, that pans out? Or I guess, we've already seen a little bit of that in prior data sets.

Question: Peter Lawson - Barclays - Analyst : Got you. nd then, is there a difference in CNS activity? I know you showed some. Is that a differentiation point compared to --

Question: Peter Lawson - Barclays - Analyst : Got you. Before we -- I definitely want to touch upon the autoimmune side of things. The trial start date for the pivotal, is that this year? How long -- what are the gating factors to start? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 12, 2025 / 2:00PM, NRIX.OQ - Nurix Therapeutics Inc at Barclays Global Healthcare Conference

Question: Peter Lawson - Barclays - Analyst : Perfect. And then, as we think about the autoimmune inflammation kind of programs, kind of what are the key milestones we should be thinking about for 2025?

Question: Peter Lawson - Barclays - Analyst : Got you. Okay. And the -- sorry, the timing around the IND, is that kind of second half?

Question: Peter Lawson - Barclays - Analyst : Okay. And then --

Question: Peter Lawson - Barclays - Analyst : I'll make it a long question. The scaffolding function of BTK, how important is that in autoimmunity versus oncology? Is that a key factor? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 12, 2025 / 2:00PM, NRIX.OQ - Nurix Therapeutics Inc at Barclays Global Healthcare Conference

Question: Peter Lawson - Barclays - Analyst : Okay. Maybe kind of a high-level question. How do you think about entering these marketplaces? Is that something you partner? Is just the process you think about it and how it kind of impacts cash burn?

Question: Peter Lawson - Barclays - Analyst : For an ex-US partner, would you go for one that would kind of cover oncology and autoimmunity (inaudible) anything (inaudible) kind of thing?

Question: Peter Lawson - Barclays - Analyst : Got you. And then, just using a degrader in autoimmunity, are there any risks of complete removing BTK versus oncology? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 12, 2025 / 2:00PM, NRIX.OQ - Nurix Therapeutics Inc at Barclays Global Healthcare Conference

Question: Peter Lawson - Barclays - Analyst : Yes. How would the BTK inhibitor kind of fit in with hemolytic anemia? Are there other BTKs already in there? Is it displacement, the combinations you would have to be working with?

Question: Peter Lawson - Barclays - Analyst : Got you. And before we finish, I'd love to touch upon your partnerships, IRAK4, STAT6. What should we be expecting this year? I know it's kind of always hard when you've got Gilead and Sanofi as a partner and how much you can disclose, but --

Question: Peter Lawson - Barclays - Analyst : Perfect. I guess, just maybe a final question of the starting dose for your BTK degrader in autoimmunity versus oncology, what's the delta that we should be thinking about?

Question: Peter Lawson - Barclays - Analyst : Perfect. Thank you so much.

Question: Peter Lawson - Barclays - Analyst : Always a pleasure talking to you. Thank you.